<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112598">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01870466</url>
  </required_header>
  <id_info>
    <org_study_id>SMCCPT-100</org_study_id>
    <nct_id>NCT01870466</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Drug Interaction Between Cilostazol and Statins</brief_title>
  <acronym>2011-11-004</acronym>
  <official_title>A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacodynamic Drug Interaction Between Cilostazol and Statins in Healthy Male Volunteer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacodynamic drug interaction between cilostazol
      and statins (simvastatin as a CYP3A substrate and rosuvastatin as a non-CYP3A substrate) in
      healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects suitable for this study will visit to the Clinical Trial Center, Samsung Medical
      Center for 7 days and pharmacodynamic samplings will be performed following the
      administration of study drugs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>lipid lowering effect</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>lipid panel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>anti-platelet effect</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>platelet aggregation test</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>C -&gt; C + S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cilostazol (C) in period 1, cilostazol + simvastatin (C+S) in period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C+S -&gt; C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cilostazol + simvastatin (C+S) in period 1, cilostazol (C) in period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S -&gt; S + C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>simvastatin (S) in period 1, simvastatin + cilostazol (S+C) in period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C + S -&gt; S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cilostazol + simvastatin (C+S) in period 1, simvastatin (S) in period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R -&gt; C + R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rosuvastatin (R) in period 1, cilostazol + rosuvastatin (C+R) in period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C + R -&gt; R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cilostazol + rosuvastatin (C+R) in period 1, rosuvastatin (R) in period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C</intervention_name>
    <description>cilostazol bid for 7 days</description>
    <arm_group_label>C -&gt; C + S</arm_group_label>
    <arm_group_label>C+S -&gt; C</arm_group_label>
    <arm_group_label>S -&gt; S + C</arm_group_label>
    <arm_group_label>C + S -&gt; S</arm_group_label>
    <arm_group_label>R -&gt; C + R</arm_group_label>
    <arm_group_label>C + R -&gt; R</arm_group_label>
    <other_name>cilostazol (C); Plettal 100 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S</intervention_name>
    <description>simvastatin qd for 7 days</description>
    <arm_group_label>C -&gt; C + S</arm_group_label>
    <arm_group_label>C+S -&gt; C</arm_group_label>
    <arm_group_label>S -&gt; S + C</arm_group_label>
    <arm_group_label>C + S -&gt; S</arm_group_label>
    <other_name>simvastatin (S); Zocor 40 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R</intervention_name>
    <description>rosuvastatin qd for 7 days</description>
    <arm_group_label>R -&gt; C + R</arm_group_label>
    <arm_group_label>C + R -&gt; R</arm_group_label>
    <other_name>Rosuvastatin (R); Crestor 20 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects aged 20 - 55 years

          -  A body mass index in the range 18.5 - 27 kg/m2

          -  Willingness to participate during the entire study period

          -  Written informed consent after being fully informed about the study procedures

        Exclusion Criteria:

          -  Any past medical history of hepatic, renal, neurologic, cardiovascular, respiratory,
             endocrine, hemato-oncologic or psychiatric disease

          -  Active bleeding or bleeding tendency

          -  History of gastrointestinal disease or surgery possibly affecting drug absorption

          -  History of clinically significant drug hypersensitivity

          -  Use of medication within 7 days before the first dose

          -  Heavy drinker (&gt;140 g/week)

          -  Whole blood donation during 60 days before the study

          -  Judged not eligible for study participation by investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Wook Ko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JaeWook Ko, MD, PhD</last_name>
      <phone>82-2-3410-3690</phone>
      <email>jw0701.ko@samsung.com</email>
    </contact>
    <investigator>
      <last_name>JaeWook Ko, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 3, 2013</lastchanged_date>
  <firstreceived_date>May 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>JaeWook  Ko</investigator_full_name>
    <investigator_title>Professor, Department of Clinical Pharmacology and Therapeutics</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Rosuvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
